Vitamin D and intervention trials in prostate cancer: from theory to therapy.
Schwartz GG.
Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
PMID: 18619854
doi:10.1016/j.annepidem.2008.03.007
This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Ang JE, Olmos D, de Bono JS.
Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
PMID: 19223900
doi:10.1038/sj.bjc.6604904
Ecological Studies Of Ultraviolet B, Vitamin D And Cancer Since 2000.
Grant WB, Mohr SB.
Ann Epidemiol. 2009 Mar 6. [Epub ahead of print]
PMID: 19269856
doi:10.1016/j.annepidem.2008.12.014
Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk.
Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H.
Aliment Pharmacol Ther. 2009 Jul 1;30(2):113-25. Epub 2009 Apr 15.
PMID: 19392870
DOI: 10.1111/j.1365-2036.2009.04022.x
Conclusions Our results support suggestions that serum 25(OH)D is inversely related to CRC risk.
Vitamin D and prevention of breast cancer: pooled analysis.
Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC.
J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11.
PMID: 17368188
CONCLUSIONS: Intake of 2000 IU/day of Vitamin D(3), and, when possible, very moderate exposure to sunlight, could raise serum 25(OH)D to 52 ng/ml, a level associated with reduction by 50% in incidence of breast cancer, according to observational studies.
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE.
Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7.
PMID: 19586795
Meta-analysis of vitamin D, calcium and the prevention of breast cancer.
Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H.
Breast Cancer Res Treat. 2009 Oct 23. [Epub ahead of print]
PMID: 19851861
These results provide strong evidence that vitamin D and calcium have a chemopreventive effect against breast cancer.